THE STRATEGY OF ANTIMICROBIAL THERAPY OF ACUTE UNCOMPLICATED PYELONEPHRITIS FROM THE POSITION OF ETIOLOGICAL DATA
https://doi.org/10.17709/2409-2231-2015-2-3-59-63
Abstract
Abstract:
Acute pyelonephritis is one of the common diseases both in outpatient and in the hospital practice. The leading causative agent of this disease is E. coli. Obstructive uropathy, foreign body, vesicoureteral reflux, sexual activity, use of local contraceptives contribute to the upward development of urinary infection. The goals of antimicrobial therapy for acute uncomplicated pyelonephritis are: relief of symptoms, restoration of social activity, prevention of complications and relapse prevention. The choice of an antimicrobial agent in most cases is carried out empirically based on the data on the dominant pathogens and their regional resistance. In acute uncomplicated pyelonephritis duration of antimicrobial therapy should be 7–14 days. The drugs of choice for treatment of acute uncomplicated pyelonephritis non-severe in adults are ciprofloxacin and levofloxacin, ceftibuten and cefixime. Patients with acute uncomplicated pyelonephritis severe emergency hospitalization is shown in urological outpatient and parenteral antimicrobial therapy (carbapenems or protected aminopenicillins combined with or without amikacin) with subsequent conversion to oral drugs and infusion therapy.
About the Authors
A. D. KaprinRussian Federation
MD, professor, corresponding member of RAS, director of NMRRC, head of the Department of urology with the course of oncourology, People’s Friendship University of Russia
A. A. Kostin
Russian Federation
MD, professor, vice director of NMRRC, head of the Department of urology, oncology and radiology FAT MW, People’s Friendship University of Russia
S. V. Popov
Russian Federation
PhD, head of department of analysis of activities and prospective programs of development of NMRRC
References
1. Prakticheskaya urologiya. Pod red. Glybochko P. V., Alyaeva Yu. G. M.: ID «Medforum», 2012. 352 s. (Russian)
2. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med 2002; 113 (Suppl 1A): 5–13.
3. Perepanova T. S., Khazan P. L. Neoslozhnennaya infektsiya nizhnikh mochevykh putei. Eksperimental’naya i klinicheskaya urologiya. 2010; 2: 78–82. (Russian)
4. Antimikrobnaya terapiya i profilaktika infektsii pochek, mochevyvodyashchikh putei i muzhskikh polovykh organov. Rossiiskie natsional’nye rekomendatsii. Pod red. Lopatkina N. A., Apolikhina O. I., Pushkarya D.Yu i dr. M., 2014. 64 s. (Russian)
5. Sidorenko S. V. Mikrobiologicheskaya kharakteristika infektsii mochevyvodyashchikh putei.//Materialy mezhdunarodnogo simpoziuma: «Infektsii mochevyvodyashchikh putei v ambulatornoi praktike» 16 fevralya 1999 g. M.,1999.s. 9–14. (Russian)
6. Sinyakova L. A., Kosova I. V. Antibakterial’naya terapiya ostrykh tsistitov. RMZh. 2005; 7: 478–481. (Russian)
7. Naber K. G., Morrissey I., Ambler J. E. Urinary Tract Infections and Fluoroquinolones. — Science Press Ltd, 2000.
Review
For citations:
Kaprin A.D., Kostin A.A., Popov S.V. THE STRATEGY OF ANTIMICROBIAL THERAPY OF ACUTE UNCOMPLICATED PYELONEPHRITIS FROM THE POSITION OF ETIOLOGICAL DATA. Research and Practical Medicine Journal. 2015;2(3):59-63. (In Russ.) https://doi.org/10.17709/2409-2231-2015-2-3-59-63